Biogen Inc. (BIIB) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 75
- Profitability 75
- Business Quality 75
- Balance Sheet 55
- Cash Flow 80
Why this rating?
Health 74/100 — High Quality
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Biogen Inc. (BIIB) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates Biogen Inc. 74/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 37.74
- Forward P/E 12.84
- PEG 1.16
- EV/Revenue 3.96
Profitability
- Revenue Growth 3.4%
- Gross Margin 78.3%
- Operating Margin 25.1%
- Net Margin 8.3%
- ROE 4.6%
Financial strength
- Cash $1.28B
- Debt $8.36B
- Net Cash $-7.07B
- Free Cash Flow $1.97B
- Current Ratio 1.87
Similar companies
Peers in Drug Manufacturers - General, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Eli Lilly and Company Drug Manufacturers - General LLY$1,123.91 86 Health 86 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- AstraZeneca PLC Drug Manufacturers - General AZN$160.04 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Gilead Sciences, Inc. Drug Manufacturers - General GILD$146.64 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- AbbVie Inc. Drug Manufacturers - General ABBV$248.78 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Bristol-Myers Squibb Company Drug Manufacturers - General BMY$64.69 72 Health 72 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Johnson & Johnson Drug Manufacturers - General JNJ$269.12 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Pfizer Inc. Drug Manufacturers - General PFE$27.79 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Amgen Inc. Drug Manufacturers - General AMGN$393.17 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Biogen Inc. (BIIB).